Bruce C Marshall

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi Influenza vaccination coverage level at a cystic fibrosis center
    Bruce C Marshall
    Intermountain Cystic Fibrosis Center, Salt Lake City, Utah, USA
    Pediatrics 109:E80-0. 2002
  2. ncbi A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, UT 84113, USA
    Pediatr Pulmonol 46:987-90. 2011
  3. ncbi Selection of patients with cystic fibrosis for lung transplantation
    Theodore G Liou
    Intermountain Cystic Fibrosis Center, Department of Internal Medicine, Division of Respiratory Critical Care and Occupational Pulmonary Medicine, University of Utah, Salt Lake City 84132, USA
    Curr Opin Pulm Med 8:535-41. 2002
  4. ncbi Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis
    Lisa Saiman
    Department of Pediatics, Columbia University, NY 10032, USA
    Am J Respir Crit Care Med 172:1008-12. 2005
  5. ncbi Priorities for lung transplantation among patients with cystic fibrosis
    Theodore G Liou
    JAMA 287:1523-4; author reply 1524-5. 2002
  6. ncbi Impact of burkholderia infection on lung transplantation in cystic fibrosis
    Susan Murray
    Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
    Am J Respir Crit Care Med 178:363-71. 2008
  7. ncbi Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review
    Virginia A Stallings
    Division of Gastroenterology, Hepatology, and Nutrition, The Children s Hospital of Philadelphia, 3535 Market St, Philadelphia, PA 19104, USA
    J Am Diet Assoc 108:832-9. 2008
  8. ncbi Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    Christian A Merlo
    The Johns Hopkins University School of Medicine, 1830 E Monument St Fifth Floor, Baltimore, MD 21205, USA
    Chest 132:562-8. 2007
  9. ncbi Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines
    Vicky A LeGrys
    Division of Clinical Laboratory Science, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7145, USA
    J Pediatr 151:85-9. 2007
  10. ncbi Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes
    Dao Nguyen
    Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    Pediatr Pulmonol 42:533-41. 2007

Collaborators

Detail Information

Publications14

  1. ncbi Influenza vaccination coverage level at a cystic fibrosis center
    Bruce C Marshall
    Intermountain Cystic Fibrosis Center, Salt Lake City, Utah, USA
    Pediatrics 109:E80-0. 2002
    ..Annual vaccination is the most effective means to prevent or attenuate this illness. The vaccine is recommended for patients with cystic fibrosis (CF) older than 6 months, but the degree of adherence with this recommendation is unknown...
  2. ncbi A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, UT 84113, USA
    Pediatr Pulmonol 46:987-90. 2011
    ..While this is of concern, it is not known if optimization of dosing strategies according to guidelines recommendations will result in clinical benefit...
  3. ncbi Selection of patients with cystic fibrosis for lung transplantation
    Theodore G Liou
    Intermountain Cystic Fibrosis Center, Department of Internal Medicine, Division of Respiratory Critical Care and Occupational Pulmonary Medicine, University of Utah, Salt Lake City 84132, USA
    Curr Opin Pulm Med 8:535-41. 2002
    ..However, judicious use of the survival model to select patients for transplantation is likely to improve survival outcomes...
  4. ncbi Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis
    Lisa Saiman
    Department of Pediatics, Columbia University, NY 10032, USA
    Am J Respir Crit Care Med 172:1008-12. 2005
    ..2% improvement in the 168-d relative change in FEV1 among azithromycin participants compared with placebo participants...
  5. ncbi Priorities for lung transplantation among patients with cystic fibrosis
    Theodore G Liou
    JAMA 287:1523-4; author reply 1524-5. 2002
  6. ncbi Impact of burkholderia infection on lung transplantation in cystic fibrosis
    Susan Murray
    Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
    Am J Respir Crit Care Med 178:363-71. 2008
    ..Infection with Burkholderia species is typically considered a contraindication to transplantation in CF. However, the risks posed by different Burkholderia species on transplantation outcomes are poorly defined...
  7. ncbi Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review
    Virginia A Stallings
    Division of Gastroenterology, Hepatology, and Nutrition, The Children s Hospital of Philadelphia, 3535 Market St, Philadelphia, PA 19104, USA
    J Am Diet Assoc 108:832-9. 2008
    ..These Registry data-based recommendations are presented...
  8. ncbi Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    Christian A Merlo
    The Johns Hopkins University School of Medicine, 1830 E Monument St Fifth Floor, Baltimore, MD 21205, USA
    Chest 132:562-8. 2007
    ..The main objective of the study was to estimate the incidence and identify risk factors for the acquisition of MARPA among individuals with CF...
  9. ncbi Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines
    Vicky A LeGrys
    Division of Clinical Laboratory Science, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7145, USA
    J Pediatr 151:85-9. 2007
  10. ncbi Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes
    Dao Nguyen
    Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    Pediatr Pulmonol 42:533-41. 2007
    ..The in vitro effect of AZM on PLC correlates with FEV(1) response to AZM. This suggests that AZM anti-virulence effects may be predictive of clinical response and play a role in the mechanism of action of AZM in CF patients...
  11. ncbi Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial
    Lisa Saiman
    Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032 3784, USA
    JAMA 290:1749-56. 2003
    ..Treatment strategies for cystic fibrosis (CF) lung disease include antibiotics, mucolytics, and anti-inflammatory therapies. Increasing evidence suggests that macrolide antibiotics might be beneficial in patients with CF...
  12. ncbi Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!
    Bruce C Marshall
    Am J Respir Crit Care Med 169:781-2. 2004
  13. ncbi Cystic fibrosis adult care: consensus conference report
    James R Yankaskas
    University of North Carolina, Chapel Hill, NC 27599, USA
    Chest 125:1S-39S. 2004
  14. ncbi Cystic fibrosis
    Bruce C Marshall
    Curr Opin Pulm Med 9:484-5. 2003